Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Long-Term Deferred Tax (2017 - 2025)

Medifast (MED) has disclosed Long-Term Deferred Tax for 9 consecutive years, with $12.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Deferred Tax rose 202.55% year-over-year to $12.1 million, compared with a TTM value of $12.1 million through Sep 2025, up 202.55%, and an annual FY2024 reading of $11.5 million, up 178.36% over the prior year.
  • Long-Term Deferred Tax was $12.1 million for Q3 2025 at Medifast, up from $11.5 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $12.1 million in Q3 2025 and bottomed at $692000.0 in Q1 2021.
  • Average Long-Term Deferred Tax over 5 years is $5.8 million, with a median of $4.4 million recorded in 2021.
  • The sharpest move saw Long-Term Deferred Tax tumbled 66.59% in 2021, then surged 788.73% in 2022.
  • Year by year, Long-Term Deferred Tax stood at $4.4 million in 2021, then grew by 20.98% to $5.3 million in 2022, then fell by 22.73% to $4.1 million in 2023, then skyrocketed by 178.36% to $11.5 million in 2024, then rose by 5.65% to $12.1 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for MED at $12.1 million in Q3 2025, $11.5 million in Q2 2025, and $11.4 million in Q1 2025.